Zheng Wang: Tumor immune infiltration and prognosis in early breast cancer
Zheng Wang, Clinical Assistant Professor at Ruijin Hospital Affiliated to Shanghai Jiao Tong University, shared on LinkedIn:
“Today, our new research article ‘Association of tumor immune infiltration and prognosis with homologous recombination repair genes mutations in early triple-negative breast cancer’ is published in Frontiers in Immunology.
In this research, we used targeted next-generating sequencing for tumor mutations in homologous recombination repair (HRR) genes in 434 early triple-negative breast (TNBC) patients from Ruijin Cohort. The frequencies of mutations were compared with public reference cohorts (320 TNBC patients from METABRIC, 105 from TCGA, and 225 from MSKCC 2018).
Our results showed that HRR genes mutations were seen in 21.89% patients, with BRCA1/2 mutations significantly enriched in tumors with breast/ovarian cancer family history and high Ki-67 levels. Furthermore, immune infiltration and PD-L1 expression was positively associated with HRR mutation, and both HRR mutation and high CD8+ T cell infiltration levels were associated with superior prognostic outcome.”
Source: Zheng Wang/LinkedIn
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023